Uterine Cervical NeoplasmsNCT06644248
AI Model for Cervical Cancer Detection From Colposcopy Images
An observational study of Uterine Cervical Neoplasms, run by Bangladesh University of Engineering and Technology at 1 site in Bangladesh.
Trial summary
Cervical cancer is a significant health issue, particularly in low-income countries, where late diagnosis and limited access to screenings contribute to high mortality rates. This study aims to develop and evaluate an artificial intelligence (AI) model to analyze colposcopic images for detecting cervical cancer more… Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Uterine Cervical Neoplasms
- What is being tested?
- Colposcopy
- How many people
- 500 participants
- Where
- 1 siteBangladesh
- Study dates
- 11 Jan 2024to 11 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study cohort will consist of women referred to colposcopy clinics due to abnormal cytology, positive HPV tests, or self-reported cervical distress requiring evaluation. Participants will be sourced from listed primary care clinics, ensuring a diverse sample across age groups and socioeconomic backgrounds for comprehensive representation. The project aims to assess the AI model's efficacy in detecting cervical anomalies in a real-world clinical context, evaluating its performance across diverse populations and addressing the unique challenges of cervical cancer screening in varied healthcare settings.
Who may be able to join
- Female patients of age 18 years or older can be selectedas subjects.
- Individuals willing to participate in cervical cancerscreening.
- Availability for colposcopic examination.
- Women with no history of hysterectomy (total removalof the uterus).
- Women with no current or prior diagnosis of cervicalcancer.
- Availability of relevant medical records forconfirmation and comparison purposes.
Who cannot join
- Pregnant women, given the potential impact onscreening results and the need for specialconsiderations during pregnancy.
- Individuals with severe medical conditions orcircumstances that may make colposcopic examinationinappropriate or unsafe.
- Patients with conditions that could interfere with theaccuracy of the screening results, such as severevaginal bleeding.
- Follow-up screenings.
Trial locations and contacts
1 site in 1 country.
Bangladesh1 site, 1 recruiting
- Recruiting
Ibn Sina Medical College Hospital
Dhaka, 1216
Nasrin Ara Zaman, FCPS, +8801715031998
About this study
Official title: Development and Evaluation of an Artificial Intelligence Model for Cervical Cancer Detection From Colposcopic Images
Cervical cancer is a significant health issue, particularly in low-income countries, where late diagnosis and limited access to screenings contribute to high mortality rates. This study aims to develop and evaluate an artificial intelligence (AI) model to analyze colposcopic images for detecting cervical cancer more accurately and efficiently. Colposcopy, a procedure used to examine the cervix for signs of cancer, relies heavily on doctors' expertise, leading to inconsistent results. The current gold standard, colposcopy-directed biopsy, is invasive and can cause complications. The hypothesis is that an AI model can outperform traditional methods in identifying cervical abnormalities, providing a reliable and scalable solution for early detection, especially in underserved areas. By automating the analysis process, the AI model aims to reduce reliance on trained personnel, making cervical cancer screening more accessible and improving early diagnosis and treatment outcomes. The study will create a diverse dataset of colposcopy images from various sources and develop the AI model. The model's performance will be validated in clinical settings, assessing its accuracy in classifying cancer stages and identifying transformation zones. The impact on early detection, patient outcomes, and model usability will be evaluated, as well as its generalizability across different healthcare environments. The goal is to enhance the accuracy and efficiency of cervical cancer screening, ultimately reducing mortality rates and improving patient care.
Read the detailed description
The study aims to develop an AI model to improve cervical cancer screening by analyzing colposcopic images. The study is a prospective and retrospective case-control study conducted at Ibn Sina Medical College Hospital in Dhaka, Bangladesh. The primary goal is to leverage deep learning techniques to enhance the accuracy and efficiency of cervical cancer detection, particularly in low-resource settings. Cervical cancer remains a significant health challenge, particularly in low- and middle-income countries where access to timely screening and treatment is limited. Colposcopy is a diagnostic procedure used to examine the cervix for signs of disease. Traditional colposcopy is highly dependent on the clinician's experience, leading to subjectivity and potential inaccuracies. This research proposes using AI to automate the analysis of colposcopic images, aiming to provide a more objective and reliable diagnostic tool. The primary objectives are to curate a comprehensive dataset of colposcopy images and develop an AI model capable of accurately classifying transformation zones and detecting cervical abnormalities. Specific objectives include clinical validation of the AI model's performance, assessing the model's usability in clinical workflows, evaluating the impact of the AI model on early detection of cervical cancer, ensuring the model's generalizability across diverse datasets, and investigating the model's effectiveness as a clinical decision support tool. Inaccuracies in traditional vision screening and a shortage of trained personnel in low-resource settings hinder effective cervical cancer screening. The AI model aims to mitigate these issues by providing an automated, scalable, and cost-effective solution. By improving the accuracy and accessibility of cervical cancer screening, this research has the potential to significantly impact patient outcomes in resource-limited environments. The study involves both prospective and retrospective data collection. Colposcopic images and relevant clinical metadata will be gathered from patients at the study sites. The data will be used to train and validate the AI model. Inclusion criteria for the study are women aged 18 or older who are willing to participate in cervical cancer screening and have no history of hysterectomy. Exclusion criteria include pregnant women and individuals with severe medical conditions that could affect screening results. The target population includes confirmed cervical cancer patients and individuals with suspected cervical abnormalities. Data from individuals with normal cervical conditions will also be included to facilitate unsupervised learning. Sample size calculations will follow established methodologies for evaluating diagnostic performance, considering factors such as sensitivity, specificity, and disease prevalence. The study includes several quality assurance measures to ensure data accuracy and reliability. A quality assurance plan addresses data validation and registry procedures, including site monitoring and auditing. Data checks will compare registry entries against predefined rules for range and consistency. Source data verification will be conducted by comparing registry data with external sources such as medical records. Standard Operating Procedures (SOPs) will cover registry operations, including patient recruitment, data collection, data management, data analysis, adverse event reporting, and change management. Sample size assessment specifies the number of participants required to demonstrate the model's effectiveness. A plan for addressing missing data includes strategies for handling unavailable or inconsistent data. The statistical analysis plan outlines the methods for evaluating the AI model's performance, including sensitivity, specificity, and accuracy metrics. The analysis will also consider the model's generalizability across different datasets and its impact on clinical decision-making and patient outcomes. This research seeks to develop an AI-based solution to improve cervical cancer screening accuracy and accessibility, particularly in low-resource settings. By addressing the limitations of traditional colposcopy and leveraging advanced computational techniques, the study aims to provide a scalable and effective tool for early detection of cervical cancer, ultimately improving patient outcomes and reducing mortality rates.
- Conditions
- Uterine Cervical Neoplasms
- Being tested
- Colposcopy
- Keywords
- Cervical Cancer, Colposcopy, Deep Learning, Transformation Zones
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ColposcopyDiagnostic test
The intervention involves the use of colposcopy, a diagnostic procedure to visually examine the cervix using a colposcope. The procedure includes the application of saline, acetic acid, and iodine solutions to enhance the visualization of cervical tissues and identify abnormalities. The dosage form includes applying these solutions directly to the cervical area. The frequency of the intervention is typically a single session per patient, with the duration of the procedure lasting approximately 10-15 minutes. This study aims to utilize an AI model to analyze the colposcopic images obtained during the procedure to improve the accuracy and efficiency of cervical cancer detection.
| Study group | Role | What they receive |
|---|---|---|
| Self reported uterine distress undergoing colposcopic evaluation | The study group consists of women undergoing cervical cancer screening. This includes those with suspected cervical abnormalities identified through initial cytology or HPV tests and referred for colposcopy. The study group also includes women without apparent cervical abnormalities to ensure a comprehensive dataset. The aim is to develop an AI model capable of accurately diagnosing cervical cancer and identifying transformation zones in colposcopic images. This diverse group allows for the evaluation of the AI model across a wide range of conditions and exposures, enhancing its generalizability and clinical utility. Receives: Diagnostic Test: Colposcopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Swede Score Evaluation
The Swede score will be used to evaluate the severity of cervical abnormalities identified in colposcopic images. This scoring system assesses various colposcopic findings, including acetowhiteness, lesion size, and vascular patterns, to determine the effectiveness of the AI model in evaluating cervical abnormalities.
Measured: 12 hours
Secondary outcomes (1)
Transformation Zone Classification Accuracy
The metric used includes accuracy, precision, recall, and F1-score for the classification of the transformation zone (TZ) in colposcopic images by the AI model. These metrics will assess the effectiveness of the AI model in identifying and classifying the transformation zone in colposcopic images.
Measured: 12 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2024
- Study start11 Jan 2024
- Primary completion11 Jan 2025 (estimated)
- Study completion11 Feb 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Uterine Cervical NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bangladesh University of Engineering and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Taufiq Hasan, PhD, Bangladesh University of Engineering and Technology
- Investigators
- Taufiq Hasan, Taufiq, Principal investigator, Department of Biomedical Engineering, BUET, Dhaka - 1205.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06644248
- Sponsor's protocol ID
- ISMC/Admin/2023/2149
- Status last verified
- Oct 2024
- First submitted
- 30 Jul 2024
- Last updated
- 16 Oct 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Evaluation of an Artificial Intelligence Model for Cervical Cancer Detection From Colposcopic Images
- ClinicalTrials.gov ID
- NCT06644248
- Acronym / sponsor ID
- ISMC/Admin/2023/2149
- Conditions
- Uterine Cervical Neoplasms
- Keywords
- Cervical Cancer, Colposcopy, Deep Learning, Transformation Zones
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Bangladesh University of Engineering and TechnologyUniversity, hospital or other
- Study start
- 11 Jan 2024 (actual)
- Primary completion
- 11 Jan 2025 (estimated)
- Study completion
- 11 Feb 2025 (estimated)
- First posted
- 16 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cervical cancer is a significant health issue, particularly in low-income countries, where late diagnosis and limited access to screenings contribute to high mortality rates. This study aims to develop and evaluate an artificial intelligence (AI) model to analyze colposcopic images for detecting cervical cancer more accurately and efficiently. Colposcopy, a procedure used to examine the cervix for signs of cancer, relies heavily on doctors' expertise, leading to inconsistent results. The current gold standard, colposcopy-directed biopsy, is invasive and can cause complications. The hypothesis is that an AI model can outperform traditional methods in identifying cervical abnormalities, providing a reliable and scalable solution for early detection, especially in underserved areas. By automating the analysis process, the AI model aims to reduce reliance on trained personnel, making cervical cancer screening more accessible and improving early diagnosis and treatment outcomes. The study will create a diverse dataset of colposcopy images from various sources and develop the AI model. The model's performance will be validated in clinical settings, assessing its accuracy in classifying cancer stages and identifying transformation zones. The impact on early detection, patient outcomes, and model usability will be evaluated, as well as its generalizability across different healthcare environments. The goal is to enhance the accuracy and efficiency of cervical cancer screening, ultimately reducing mortality rates and improving patient care.
Detailed description
The study aims to develop an AI model to improve cervical cancer screening by analyzing colposcopic images. The study is a prospective and retrospective case-control study conducted at Ibn Sina Medical College Hospital in Dhaka, Bangladesh. The primary goal is to leverage deep learning techniques to enhance the accuracy and efficiency of cervical cancer detection, particularly in low-resource settings. Cervical cancer remains a significant health challenge, particularly in low- and middle-income countries where access to timely screening and treatment is limited. Colposcopy is a diagnostic procedure used to examine the cervix for signs of disease. Traditional colposcopy is highly dependent on the clinician's experience, leading to subjectivity and potential inaccuracies. This research proposes using AI to automate the analysis of colposcopic images, aiming to provide a more objective and reliable diagnostic tool. The primary objectives are to curate a comprehensive dataset of colposcopy images and develop an AI model capable of accurately classifying transformation zones and detecting cervical abnormalities. Specific objectives include clinical validation of the AI model's performance, assessing the model's usability in clinical workflows, evaluating the impact of the AI model on early detection of cervical cancer, ensuring the model's generalizability across diverse datasets, and investigating the model's effectiveness as a clinical decision support tool. Inaccuracies in traditional vision screening and a shortage of trained personnel in low-resource settings hinder effective cervical cancer screening. The AI model aims to mitigate these issues by providing an automated, scalable, and cost-effective solution. By improving the accuracy and accessibility of cervical cancer screening, this research has the potential to significantly impact patient outcomes in resource-limited environments. The study involves both prospective and retrospective data collection. Colposcopic images and relevant clinical metadata will be gathered from patients at the study sites. The data will be used to train and validate the AI model. Inclusion criteria for the study are women aged 18 or older who are willing to participate in cervical cancer screening and have no history of hysterectomy. Exclusion criteria include pregnant women and individuals with severe medical conditions that could affect screening results. The target population includes confirmed cervical cancer patients and individuals with suspected cervical abnormalities. Data from individuals with normal cervical conditions will also be included to facilitate unsupervised learning. Sample size calculations will follow established methodologies for evaluating diagnostic performance, considering factors such as sensitivity, specificity, and disease prevalence. The study includes several quality assurance measures to ensure data accuracy and reliability. A quality assurance plan addresses data validation and registry procedures, including site monitoring and auditing. Data checks will compare registry entries against predefined rules for range and consistency. Source data verification will be conducted by comparing registry data with external sources such as medical records. Standard Operating Procedures (SOPs) will cover registry operations, including patient recruitment, data collection, data management, data analysis, adverse event reporting, and change management. Sample size assessment specifies the number of participants required to demonstrate the model's effectiveness. A plan for addressing missing data includes strategies for handling unavailable or inconsistent data. The statistical analysis plan outlines the methods for evaluating the AI model's performance, including sensitivity, specificity, and accuracy metrics. The analysis will also consider the model's generalizability across different datasets and its impact on clinical decision-making and patient outcomes. This research seeks to develop an AI-based solution to improve cervical cancer screening accuracy and accessibility, particularly in low-resource settings. By addressing the limitations of traditional colposcopy and leveraging advanced computational techniques, the study aims to provide a scalable and effective tool for early detection of cervical cancer, ultimately improving patient outcomes and reducing mortality rates.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Self reported uterine distress undergoing colposcopic evaluation | – | Diagnostic Test: ColposcopyThe study group consists of women undergoing cervical cancer screening. This includes those with suspected cervical abnormalities identified through initial cytology or HPV tests and referred for colposcopy. The study group also includes women without apparent cervical abnormalities to ensure a comprehensive dataset. The aim is to develop an AI model capable of accurately diagnosing cervical cancer and identifying transformation zones in colposcopic images. This diverse group allows for the evaluation of the AI model across a wide range of conditions and exposures, enhancing its generalizability and clinical utility. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study cohort will consist of women referred to colposcopy clinics due to abnormal cytology, positive HPV tests, or self-reported cervical distress requiring evaluation. Participants will be sourced from listed primary care clinics, ensuring a diverse sample across age groups and socioeconomic backgrounds for comprehensive representation. The project aims to assess the AI model's efficacy in detecting cervical anomalies in a real-world clinical context, evaluating its performance across diverse populations and addressing the unique challenges of cervical cancer screening in varied healthcare settings.
Key inclusion criteria (6 listed)
- Female patients of age 18 years or older can be selectedas subjects.
- Individuals willing to participate in cervical cancerscreening.
- Availability for colposcopic examination.
- Women with no history of hysterectomy (total removalof the uterus).
- Women with no current or prior diagnosis of cervicalcancer.
Key exclusion criteria (4 listed)
- Pregnant women, given the potential impact onscreening results and the need for specialconsiderations during pregnancy.
- Individuals with severe medical conditions orcircumstances that may make colposcopic examinationinappropriate or unsafe.
- Patients with conditions that could interfere with theaccuracy of the screening results, such as severevaginal bleeding.
- Follow-up screenings.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ColposcopyThe intervention involves the use of colposcopy, a diagnostic procedure to visually examine the cervix using a colposcope. The procedure includes the application of saline, acetic acid, and iodine solutions to enhance the visualization of cervical tissues and identify abnormalities. The dosage form includes applying these solutions directly to the cervical area. The frequency of the intervention is typically a single session per patient, with the duration of the procedure lasting approximately 10-15 minutes. This study aims to utilize an AI model to analyze the colposcopic images obtained during the procedure to improve the accuracy and efficiency of cervical cancer detection. | Diagnostic test | Self reported uterine distress undergoing colposcopic evaluation |
Primary outcome
Swede Score Evaluation
Time frame: 12 hours
The Swede score will be used to evaluate the severity of cervical abnormalities identified in colposcopic images. This scoring system assesses various colposcopic findings, including acetowhiteness, lesion size, and vascular patterns, to determine the effectiveness of the AI model in evaluating cervical abnormalities.
1 secondary outcome
Transformation Zone Classification Accuracy
Time frame: 12 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2024.
- Individual participant dataSharing planned: No
Related trials for Uterine Cervical Neoplasms
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 4
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Cervical Cancer
Recruiting
Use Misoprostol to Optimize Prevention of Cervical Cancer
Cervical Cancers
RecruitingObservational study
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
Cervical Cancer, Cervical Dysplasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Taufiq Hasan, Taufiq principal investigator
Department of Biomedical Engineering, BUET, Dhaka - 1205.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Uterine Cervical Neoplasms, run by Bangladesh University of Engineering and Technology at 1 site in Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Taufiq Hasan, PhD (+8801817579844, taufiq@bme.buet.ac.bd), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Swede Score Evaluation (time frame: 12 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2024.